Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
The Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following further analysis with an additional 49 symptomatic COVID-19 cases.
Details of the COVID-19 vaccine findings
After scrutiny from the US National Institute of Allergy and Infectious Diseases for purportedly out-of-date data in the original…
-
Noosa News14 hours agoShocking moment Bradley Donald Towle arrested after Bruce Hwy rampage and shooting on Sunshine coast
-
General15 hours agoNSW Police to provide update on Sydney woman’s kidnap from Bankstown home and killing
-
Noosa News21 hours agoMollie O’Callaghan admits to doubts, wins gold at Australian Open Swimming Championships
-
Noosa News14 hours agoQueensland woman charged with murdering partner with MND allegedly fed him ‘cocktail’ of medications